ArticleOncology letters2017

Therapy with transcutaneous administration of imiquimod combined with oral administration of sorafenib suppresses renal cell carcinoma growing in an orthotopic mouse model.

Takashi Karashima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.